A once-weekly injection consisting of a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg (Wegovy) led to ...

Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.

The largest project underway is Novo Nordisk’s $4.1 billion expansion in Johnston County. The Danish drugmaker in 2024 began ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Evercore ISI raised the firm’s price target on Ascendis Pharma (ASND) to $220 from $205 and keeps an Outperform rating on the shares. The ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Ascendis Pharma (ASND) announced that YORVIPATH is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone, administered once-daily, designed to ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, ...